Committee Chairman Lamar Alexander (R-Tenn.) mentioned earlier than the vote that Hahn is “precisely the kind of nominee” that ought to lead the FDA, citing his administration and analysis expertise.
However Sen. Patty Murray (D-Wash.), the panel’s rating Democrat, voted in opposition to Hahn, saying throughout his affirmation listening to final month he had “refused to decide to implementing a robust coverage to clear nontobacco e-cigarettes” from the market — a step President Trump promised in September however has not finalized. Different Democrats break up, with some voting for Hahn’s affirmation and others voting in opposition to him.
The timing of the total Senate vote isn’t recognized however Alexander has mentioned he hoped Hahn could be confirmed by the top of the 12 months.
Throughout his affirmation listening to, Hahn ducked questions from senators sad concerning the Trump administration’s failure to ban flavored e-cigarettes. Hahn mentioned he was alarmed by 2019 knowledge exhibiting that nearly 28 % of excessive schoolers have vaped within the final 30 days, however mentioned he didn’t need to prejudge the administration’s e-cigarette coverage as a result of he hasn’t been concerned in creating it. He vowed to make use of “science and knowledge” to handle that situation and others.
In a letter Monday, 28 members of Congress requested Trump to take away flavored e-cigarettes from the market till they’re cleared by the FDA. Vaping advocates have argued that a taste ban would damage adults utilizing e-cigarettes to give up smoking and that youth use needs to be diminished in different methods, similar to by limiting the place the merchandise are bought.
Dozens of medical, affected person and analysis teams on Monday urged his fast affirmation, saying the company wants a everlasting commissioner. However a number one tobacco-control group, Marketing campaign for Tobacco-Free Children, mentioned Hahn shouldn’t be confirmed till the administration points a vaping coverage.
The Trump administration’s first FDA head, Scott Gottlieb, stepped down in April and was changed by performing commissioner Norman “Ned” Sharpless. Final month, Sharpless returned to his earlier submit as director of the Nationwide Most cancers Institute, and Brett Giroir, a high official on the Division of Well being and Human Providers, succeeded him as performing FDA commissioner.